Key result
Glycoprotein IIb-IIIa inhibitors do not increase overall ICH risk, though abciximab increases symptomatic ICH.
Why the study?
The safety profile and application coverage of glycoprotein IIb-IIIa inhibitors in stroke-related treatment remained unclear.
Does the administration of Glycoprotein IIb-IIIa inhibitors prevent arterial reocclusion without increasing intracranial hemorrhage or mortality in patients with acute ischemic stroke?
Meta-Analysis (n=3,700)
Does the administration of Glycoprotein IIb-IIIa inhibitors prevent arterial reocclusion without increasing intracranial hemorrhage or mortality in patients with acute ischemic stroke?
Tirofiban and eptifibatide may be considered safe at low doses in acute ischemic stroke, while abciximab increases the risk of symptomatic hemorrhage and should be used with caution.
Answers are grounded in this paper and cite their sources.
Abciximab warrants caution for symptomatic ICH in acute ischemic stroke; extends RCT safety signals while overall class effect on ICH remains inconclusive.
Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible antiplatelet agents that emerged as promising therapeutic agents for AIS about 10 years ago. Given the unclear safety profile and application coverage of GP inhibitors, we conducted this meta-analysis to explore the same. Methods: We used GP IIb-IIIa inhibitors, intracranial hemorrhage, and mortality as the key words on Medline, Web of Science, and the Embase databases. Randomized controlled trials, prospective literatures, and retrospective studies in English published between 1990 and 2020 were screened. The outcomes were relative risk (RR) of death and 90-day intracerebral hemorrhage (ICH). We pooled the results in 2 categories and conducted a subgroup analysis stratified by different drugs. The choice of the effects model depended on the value of I 2 . Results: In all, 3700 patients from 20 studies were included. No GP IIb-IIIa inhibitors were found to have a remarkable influence on the ICH rate. The RR values of symptomatic ICH for abciximab and eptifibatide were 4.26 (1.89, 9.59) and 0.17 (0.04, 0.69), respectively. Both tirofiban and abciximab could decrease the mortality rate within 90 days. Age > 70 years, National Institutes of Health Stroke Scale > 15, and overall dose > 10 mg are risk factors for ICH events with tirofiban usage. Thrombectomy combined with tirofiban was safe for arterial reocclusion prevention. Conclusions: In stroke-related treatment, administration of GP IIb-IIIa inhibitors could be safe, but care should be taken regarding drug species and doses. Abciximab can increase the risk of symptomatic intracranial hemorrhage. Tirofiban and eptifibatide can be considered safe in low doses. Suitable patients should be selected using strict criteria.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2020) conducted a meta-analysis in Acute ischemic stroke (n=3,700). Glycoprotein IIb-IIIa inhibitors vs. Placebo, aspirin, or open-control was evaluated on 90-day intracerebral hemorrhage (ICH) across all study types (RR 1.21, 95% CI 0.90-1.62). Glycoprotein IIb-IIIa inhibitors did not increase the risk of intracerebral hemorrhage overall, though abciximab increased the risk of symptomatic intracerebral hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: